Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:activeDuring |
recombinant varicella zoster virus glycoprotein E
|
| gptkbp:ADC |
AS01B
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Shingrix
|
| gptkbp:clinicalTrials |
Phase III trials
adults aged 50 and older prevent herpes zoster prevent postherpetic neuralgia |
| gptkbp:contraindication |
immunocompromised individuals
severe allergic reaction to components |
| gptkbp:developedBy |
gptkb:GlaxoSmithKline
|
| gptkbp:diseaseResistance |
two doses required
|
| gptkbp:dosageForm |
injection
two doses |
| gptkbp:evaluates |
over 90%
|
| gptkbp:healthcare |
two doses recommended
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shingrix
|
| gptkbp:incubationPeriod |
2 to 8 degrees Celsius
|
| gptkbp:lastProduced |
2017
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:marketSegment |
ongoing
|
| gptkbp:notable_player |
subunit vaccine
reduces risk of postherpetic neuralgia reduces risk of shingles high efficacy in older adults intramuscular injection in deltoid muscle must be stored in a refrigerator not for immunocompromised patients not for those with severe allergies FDA_approved EMA_approved Health_Canada_approved TGA_approved |
| gptkbp:patentAssignee |
gptkb:GlaxoSmithKline
|
| gptkbp:provides |
prevention of shingles
|
| gptkbp:route |
intramuscular
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sequel |
2 to 6 months after first dose
|
| gptkbp:sideEffect |
fatigue
headache muscle pain fever pain at injection site common side effects include fatigue common side effects include fever common side effects include headache common side effects include muscle pain |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitableFor |
50 years and older
|
| gptkbp:team |
recommended for older adults
|
| gptkbp:type |
recombinant zoster vaccine
|